<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966301</url>
  </required_header>
  <id_info>
    <org_study_id>GMED16-001</org_study_id>
    <nct_id>NCT02966301</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide</brief_title>
  <acronym>GvHD-ATO</acronym>
  <official_title>Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medsenic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fovea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medsenic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the early chronic GvHD events (first line therapy), if the&#xD;
      addition of arsenic trioxide to standard therapy with corticosteroids, with or without&#xD;
      cyclosporine, will be effective in controlling chronic GvHD and to reduce the duration of&#xD;
      corticosteroid therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Graft-versus-host disease (GvHD) is the most common long-term complication in patients who&#xD;
      underwent allogeneic transplantation.&#xD;
&#xD;
      First-line therapy for chronic GVHD is based on immunosuppressive agents (corticosteroids&#xD;
      with or without cyclosporine) achieving satisfactory response in around 30% of patients.&#xD;
&#xD;
      This is a prospective, national, multicenter, non-randomized Phase II study that will include&#xD;
      a total number of 24 patients in which, trioxide d'arsenic will be administrated at&#xD;
      0,15mg/kg/day.&#xD;
&#xD;
      Clinical response will be evaluated based on the Working Group Report 2015, published by the&#xD;
      National Institute of Health Consensus.&#xD;
&#xD;
      Follow-up visits will be weekly for four weeks (ATO cycle), every two weeks from second to&#xD;
      third month of ATO treatment, every month from the fourth to sixth month of ATO treatment and&#xD;
      every 3 months, at 9 months and 12 months (final visit).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with complete or partial remission of Chronic Graft versus Host Disease after a first line treatment with Arsenic Trioxide</measure>
    <time_frame>six months</time_frame>
    <description>Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus : Lee SJ et al. Biol Blood Marrow Transplant, 2015 (cGvHD activity assessment Clinician Form A &amp; cGvHD assessment patient self-report Form B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroid dose reduction (mg/kg/day of prednisone)</measure>
    <time_frame>2 weeks and 3, 6, 9 &amp; 12 months after ATO cycle treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life self-reported by patient using the Lee Symptom Scale (LSS)</measure>
    <time_frame>6 &amp; 14 week, 6, 9 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life self-reported by patient using the Functional Assessment of Chronic Illness : Therapy with Bone Marrow Transplantation subscale (FACT-BMT)</measure>
    <time_frame>6 &amp; 14 week, 6, 9 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time without relapse in case of positive response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Follow-up throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test of immunoglobulins</measure>
    <time_frame>Inclusion, 6 &amp; 14 week, 6, 9 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test of arsenic</measure>
    <time_frame>D2, D3, D4, D5, D8, D12, D17 and D24, during arsenic trioxide treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Chronic Graft-Versus-Host Disease</condition>
  <condition>Immune System Diseases</condition>
  <arm_group>
    <arm_group_label>interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm : Arsenic trioxide Injectable Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide Injectable Solution</intervention_name>
    <description>Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).&#xD;
Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.&#xD;
The study duration will be 2 years (12 months recruitment + 12 months follow-up).</description>
    <arm_group_label>interventional</arm_group_label>
    <other_name>Trisenox / Arscimed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥18 years) who have received a first allogeneic stem cell&#xD;
             transplantation for a hematological disease (any source of hematopoietic stem cells is&#xD;
             authorized; any category of conditioning regimen prior to allo-SCT is authorized; any&#xD;
             type of stem cell donors is authorized)&#xD;
&#xD;
          -  Confirmed diagnosis of a first episode of chronic GvHD requiring systemic&#xD;
             immunosuppressive therapy (any prior GvHD prophylaxis previously used is accepted).&#xD;
             Chronic GvHD diagnosis is defined according to the NIH Working Group Consensus.&#xD;
             Chronic GvHD diagnosis will be based on the evaluation of the severity of the&#xD;
             different clinical manifestations including:&#xD;
&#xD;
               -  Performance status evaluation&#xD;
&#xD;
               -  Cutaneous evaluation measured by the percentage of extension or the presence of&#xD;
                  sclerotic features. If relevant, confirmation with a biopsy should be performed&#xD;
                  whenever possible&#xD;
&#xD;
               -  Oral symptoms&#xD;
&#xD;
               -  Ocular symptoms&#xD;
&#xD;
               -  Gastro-intestinal symptoms&#xD;
&#xD;
               -  Evaluation of liver involvement (total bilirubin, transaminases and alkaline&#xD;
                  phosphatases)&#xD;
&#xD;
               -  Pulmonary function evaluation&#xD;
&#xD;
               -  Evaluation of the musculoskeletal manifestations, especially the amplitude of the&#xD;
                  relevant articulations&#xD;
&#xD;
               -  Genital tract symptoms&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Absence of contra-indications to the use of ATO&#xD;
&#xD;
          -  Subjects affiliated with an appropriate social security system&#xD;
&#xD;
          -  Men must use a medically acceptable method of contraception throughout the treatment&#xD;
             period and for at least 4 months and 10 days following the last treatment&#xD;
             administration&#xD;
&#xD;
          -  Women who are of childbearing potential must have a negative serum pregnancy test and&#xD;
             agree to use a medically acceptable method of contraception throughout the study and&#xD;
             for 3 months following the end of the study&#xD;
&#xD;
          -  Patient not participating or not having participated in a clinical study in the 30&#xD;
             days prior to his/her inclusion in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient developing acute GvHD (whether early or &quot;late onset&quot; form)&#xD;
&#xD;
          -  Patients developing overlap GvHD as defined by the 2014 NIH Working Group Consensus&#xD;
             (presence of one or more acute GvHD manifestations in a patient with a diagnosis of&#xD;
             chronic GvHD)&#xD;
&#xD;
          -  A &quot;mild&quot; form of chronic GvHD not requiring systemic immunosuppressive therapy&#xD;
&#xD;
          -  A &quot;moderate&quot; form of chronic GvHD limited to one organ site not requiring systemic&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Patient receiving mycophenolate mofetil&#xD;
&#xD;
          -  Not the first episode of chronic GvHD needing systemic immunosuppressive therapy&#xD;
&#xD;
          -  Second allogeneic stem cell transplant&#xD;
&#xD;
          -  Severe cardiac diseases (congestive heart failure (NYHA class III), recent myocardial&#xD;
             infarction (in the past 6 months before the inclusion), histories of unexplained&#xD;
             syncope, ...)&#xD;
&#xD;
          -  Significant arrhythmias, electrocardiogram (EKG) abnormalities:&#xD;
&#xD;
          -  Congenital QT syndromes&#xD;
&#xD;
          -  History or presence of significant ventricular or atrial tachyarrhythmia&#xD;
&#xD;
          -  Clinically significant resting bradycardia (&lt; 50 beats per minutes)&#xD;
&#xD;
          -  QTc&gt;450msecformenand&gt;470msecfor women on screening EKG (using the QTcF formula)&#xD;
&#xD;
          -  Right bundle branch block plus left anterior hemiblock, bifascicular block&#xD;
&#xD;
          -  Central or peripheral neuropathy&#xD;
&#xD;
          -  Neutrophils &lt; 0.5 × 109/L&#xD;
&#xD;
          -  Platelets &lt; 50 × 109/L&#xD;
&#xD;
          -  Potassium ≤ 4 mEq/l*&#xD;
&#xD;
          -  Magnesium ≤ 1.8 mg/dl*&#xD;
&#xD;
          -  Calcium ≤ 2.15 mmol/l*&#xD;
&#xD;
          -  Hepatic impairment due to a suspected or proven liver damage, other than direct&#xD;
             hepatic cGvHD involvement&#xD;
&#xD;
          -  PT &lt; 50%&#xD;
&#xD;
          -  Renal impairment (creatinine ≥ 100 μmol/l)&#xD;
&#xD;
          -  Uncontrolled systemic infection which in the opinion of the investigator is associated&#xD;
             with an increased risk of the patients' death within 1 month after the start of&#xD;
             therapy&#xD;
&#xD;
          -  Severe neurological or psychiatric disorders&#xD;
&#xD;
          -  Denied informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Women breastfeeding at selection and throughout the treatment period&#xD;
&#xD;
               -  If abnormal at selection, to be corrected and re-validated following electrolytes&#xD;
                  infusion, before inclusion and each drug perfusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Mohty, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Antoine, AP-HP - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Huyhn, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Universitaire du Cancer - Oncopole - Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvain Chantepie, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut d'Hématologie de Basse Normandie - CHU de Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Chevallier, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôtel Dieu - CHU Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didier Blaise, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli Calmettes - Centre de Recherche en Cancérologie de Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Ceballos, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Eloi - Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Turlure, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edouard Forcade, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Caen - Institut d'Hématologie de Basse Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes - Département d'hématologie - Centre de Recherche en Cancérologie de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu - Service Hématologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine - Hématologie et thérapie cellulaire - AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer - Oncopole - Service d'Hématologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c GvHD</keyword>
  <keyword>Arsenic Trioxyde</keyword>
  <keyword>Hematology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

